soul trial oral semaglutide cardiovascular outcomes 2025 results (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine soul trial oral semaglutide cardiovascular

Safety and efficacy of the SNAP 12-hour acetylcysteine regimen for the treatment of paracetamol overdose

A licensed provider determines which medication is appropriate for each patient no specific medication is guaranteed

All plans include medication, virtual provider visits, and nutritionist coaching for one monthly price

GLP1 medications are moving rapidly from niche treatment to mainstream force, with implications that stretch far beyond weight loss alone

Recently, the newly developed drug tirzepatide, which targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was introduced to the market to treat type 2 diabetes and obesity in 2022 and 2023, respectively (Table 1)

Where it is limited or early-stage, it says that too - because the reader who gets accurate information is the one who makes a confident purchase decision, and that is the only kind of conversion worth having